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Abstract
The interaction between fat deposition and inflammation during obesity contributes to the development of non-alcoholic
fatty liver disease (NAFLD). The present study examined the effects of palmitoleate, a monounsaturated fatty acid (16:1n7),
on liver metabolic and inflammatory responses, and investigated the mechanisms by which palmitoleate increases
hepatocyte fatty acid synthase (FAS) expression. Male wild-type C57BL/6J mice were supplemented with palmitoleate and
subjected to the assays to analyze hepatic steatosis and liver inflammatory response. Additionally, mouse primary
hepatocytes were treated with palmitoleate and used to analyze fat deposition, the inflammatory response, and sterol
regulatory element-binding protein 1c (SREBP1c) activation. Compared with controls, palmitoleate supplementation
increased the circulating levels of palmitoleate and improved systemic insulin sensitivity. Locally, hepatic fat deposition and
SREBP1c and FAS expression were significantly increased in palmitoleate-supplemented mice. These pro-lipogenic events
were accompanied by improvement of liver insulin signaling. In addition, palmitoleate supplementation reduced the
numbers of macrophages/Kupffer cells in livers of the treated mice. Consistently, supplementation of palmitoleate
decreased the phosphorylation of nuclear factor kappa B (NF-kB, p65) and the expression of proinflammatory cytokines.
These results were recapitulated in primary mouse hepatocytes. In terms of regulating FAS expression, treatment of
palmitoleate increased the transcription activity of SREBP1c and enhanced the binding of SREBP1c to FAS promoter.
Palmitoleate also decreased the phosphorylation of NF-kB p65 and the expression of proinflammatory cytokines in cultured
macrophages. Together, these results suggest that palmitoleate acts through dissociating liver inflammatory response from
hepatic steatosis to play a unique role in NAFLD.
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Introduction
Obesity greatly increases the incidence of non-alcoholic fatty
liver disease (NAFLD), which is defined by fat deposition in
hepatocytes (hepatic steatosis) [1,2]. When the liver develops
overt inflammation and damage, simple steatosis progresses to
steatohepatitis, which is increasingly recognized as an essential
causal factor of terminal liver diseases such as cirrhosis and
hepatocellular carcinoma [2,3]. A number of approaches
including weight loss, metformin, insulin sensitization by
thiazolidinediones, bariatric surgery, and liver transplantation
have been considered for managing NAFLD [3–7]. However,
the effective treatment for steatohepatitis is still lacking due
largely to the absence of a clear understanding of how simple
steatosis progresses to steatohepatitis.
Because NAFLD is highly prevalent in obese populations [6],
insulin resistance, a common consequence of obesity, is thought to
critically contribute to the pathogenesis of NAFLD. Mechanisti-
cally, insulin resistance at both hepatic and systemic levels, along
with hyperinsulinemia, acts to increase the expression of genes for
lipogenic enzymes such as acetyl-CoA carboxylase 1 (ACC1) and
fatty acid synthase (FAS) [8,9] and to decrease the expression of
genes for enzymes of fatty acid oxidation including carnitine
palmitoyltransferase 1a (CPT1a) [10]. These changes, in turn,
bring about hepatic steatosis. As a primary ‘‘hit’’, fat deposition is
sufficient to trigger inflammatory responses as evidenced in
cultured hepatocytes [11,12], and to induce liver insulin resistance
by activating protein kinase Ce in mice [13]. Moreover, fat
deposition makes hepatocytes more vulnerable to a ‘‘second hit’’,
i.e., inflammatory mediators derived from adipose tissue during
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39286obesity [2]. When combined, these two ‘‘hits’’ exacerbate aspects
of NAFLD, in particular liver inflammatory response, and advance
steatosis to steatohepatitis. As reviewed elsewhere, there likely
exists a vicious cycle among hepatocyte fat deposition, liver
inflammatory response, and hepatic insulin resistance in the
development of steatohepatitis [1,2]. At this point, clear-cut causal
relationships among aspects of NAFLD within the vicious cycle
remain to be investigated.
Palmitoleate is a monounsaturated fatty acid (16:1n7) that is
available from dietary sources and is also produced endogenously
by adipocytes. Since the characterization of palmitoleate as
a bioactive lipid that coordinates metabolic crosstalk between
the liver and adipose tissue [14], increased attention has paid to
the pathophysiological relevance of palmitoleate to a wide variety
of metabolic diseases including NAFLD. However, subsequent
studies provide controversial findings regarding the effects of
palmitoleate on hepatic steatosis and/or lipogenesis that critically
contribute to the development of NAFLD. As documented in two
lines of mouse studies [14,15], palmitoleate inhibits hepatic FAS
expression, and is thought to decrease hepatic steatosis. In
contrast, human studies demonstrate that the circulating levels of
palmitoleate positively correlate with the degree of hepatic
steatosis [16], as well as adiposity that promotes fat deposition in
hepatocytes [17,18]. A direct effect of palmitoleate on inducing
hepatocyte fat deposition has also been documented [19], but lacks
in vivo validation. To date, precisely how palmitoleate regulates
hepatic FAS expression in relation to lipogenesis is not clear.
Palmitoleate is also shown to decrease palmitate-induced phos-
phorylation of c-Jun N-terminal kinase (JNK) in Huh7 hepatocytes
[19]. This finding is exciting; given the essential role for
inflammation in the development of steatohepatitis. However,
the anti-inflammatory effect of palmitoleate has not yet been
validated in vivo. The present study provides evidence to support
a unique role for palmitoleate in dissociating liver inflammatory
response from hepatic steatosis. Additionally, a novel mechanism
for palmitoleate induction of FAS expression is investigated.
Results
Palmitoleate Supplementation Improves Systemic Insulin
Sensitivity in LFD-fed Mice
Wild-type mice were fed a low-fat diet (LFD, Table 1) and
treated with or without palmitoleate. Since palmitoleate was
conjugated with bovine serum albumin (BSA), the latter was used
as negative control. Additionally, oleate was used as fatty acid
control. Compared with controls, palmitoleate supplementation
significantly increased plasma levels of palmitoleate (Figure 1A)
without significantly altering liver lipid profile (Figure S1).
Consequently, palmitoleate-supplemented mice, but not control
mice, showed improvement in systemic insulin sensitivity and
glucose metabolic homeostasis (Figure 1B–E, and Table 2).
Because food intake of palmitoleate-supplemented mice did not
differ from that of control mice, the observed insulin-sensitizing
effect, as well as alterations of hepatic steatosis and liver
inflammatory response upon palmitoleate supplementation (see
below), is not due to a decrease in energy intake.
Palmitoleate Supplementation Increases Fat Deposition,
Improves Insulin Signaling, and Decreases the
Inflammatory Response in Livers of LFD-fed Mice
Given the positive correlation between the circulating levels of
palmitoleate and hepatic steatosis in human subjects [16], the
effect of palmitoleate on hepatic lipogenesis was determined.
Because metabolic parameters of BSA-supplemented mice did not
differ from those of oleate-supplemented mice, comparisons of the
following data were made only between BSA-supplemented mice
and palmitoleate-supplemented mice. Compared with controls,
Table 1. Composition of diets.*
LFD HFD
g% kcal% g% kcal%
Casein 18.96 19.72 25.84 19.72
L-Cystine 0.28 0.30 0.39 0.30
Corn Starch 29.86 31.06 0.00 0.00
Maltodextrin 3.32 3.45 16.15 12.32
Sucrose 33.17 34.51 8.89 6.78
Cellulose 4.74 0.00 6.46 0.00
Soybean Oil 2.37 5.55 3.23 5.55
Lard 1.90 4.44 31.66 54.35
*Data were calculated based on the information provided by the vender.
doi:10.1371/journal.pone.0039286.t001
Figure 1. Improvement of systemic insulin sensitivity in LFD-
fed mice. Male C57BL/6J mice, at 5–6 weeks of age, were fed a low-fat
diet for 12 weeks and supplemented with palmitoleate (PO), oleate
(Ole), or bovine serum albumin (BSA) for the last 4 weeks. (A) Plasma
lipid profile. (B) Insulin tolerance tests (ITT). (C) Area under curve (AUC)
was calculated based on ITT. (D) Glucose tolerance tests (GTT). (E) AUC
was calculated based on GTT. For B and D, mice were fasted for 4 hrs
and received an intraperitoneal injection of insulin (0.5 U/kg) (B) or
glucose (2 g/kg) (D). Data are means 6 SE, n=4–6.
{, P,0.05
palmitoleate vs. BSA (in A – E) or oleate for the same time point (in B
and D); *, P,0.05 and **, P,0.01 palmitoleate vs. oleate (in A, C, and E);
{, P,0.05 oleate vs. BSA (in A).
doi:10.1371/journal.pone.0039286.g001
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liver fat deposition (Figure 2A). Additionally, palmitoleate-
supplemented mice exhibited a marked increase in liver expression
of genes for lipogenesis including sterol regulatory element-binding
protein 1c (SREBP1c) and FAS, but not in liver expression of
genes for fatty acid oxidation and very low density lipoprotein
(VLDL) secretion such as CPT1a and VLDL receptor (VLDLr)
(Figure 2B). When liver insulin signaling was analyzed, palmitole-
ate-supplemented mice exhibited a significant increase in insulin-
stimulated Akt (Ser473) phosphorylation in livers (Figure 2C).
Thus, palmitoleate induces hepatic steatosis while improving liver
insulin sensitivity.
It remains largely unknown if palmitoleate alters liver in-
flammatory status, an essential factor that drives the progression of
simple steatosis to steatohepatitis. Upon palmitoleate supplemen-
tation, the mice displayed a significant decrease in liver
macrophage infiltration (17% vs. 33%, Figure 2D and Figure
S2) compared with controls. Additionally, nuclear factor kappa B
(NF-kB) p65 (Ser468) phosphorylation and tumor necrosis factor
alpha (TNFa) and interleukin 6 (IL-6) expression in palmitoleate-
supplemented mice were much lower than their respective levels in
control mice (Figure 2E and F). Together, these results suggest that
palmitoleate is an anti-inflammatory bioactive lipid that dissociates
liver inflammatory response from hepatic steatosis; given the
increase in liver fat deposition in palmitoleate-supplemented mice.
Palmitoleate Dissociates Insulin Resistance and Liver
Inflammatory Response from Hepatic Steatosis in HFD-
fed Mice
To confirm if palmitoleate brings about dissociation of insulin
resistance, liver inflammatory response, and hepatic steatosis in
mouse models of diet-induced obesity, wild-type mice were fed
a high-fat diet (HFD, Table 1) and treated with or without
palmitoleate. Compared with controls, palmitoleate supplementa-
tion improved systemic insulin sensitivity and glucose metabolic
homeostasis in HFD-fed mice (Figure 3A–D). Additionally, in
HFD-fed mice, palmitoleate supplementation caused a significant
increase in hepatic levels of triglycerides and a significant decrease
in the phosphorylation of NF-kB p65 (Ser468) in livers of the
treated mice compared with controls (Figure 3 E and F). Thus,
palmitoleate supplementation also dissociates insulin resistance
and liver inflammatory response from hepatic steatosis in mice
with diet-induced obesity.
Palmitoleate Increases Fat Deposition, Stimulates FAS
Expression, and Activates SREBP1c in Hepatocytes
The direct effect of palmitoleate on fat deposition was examined
in primary mouse hepatocytes. The dose of palmitoleate used was
chosen based on published literature [20,21]. As controls, the
present study also examined lipid accumulation in primary mouse
hepatocytes supplemented with oleate, whose dose was also chosen
based on published literature [21,22]. Compared with oleate and/
or BSA, palmitoleate supplementation caused a slight but
significant increase in lipid accumulation under the basal condition
(BSA) (Figure 4A, top panels; quantitative data were shown in
Figure S3). In the presence of palmitate, palmitoleate supplemen-
tation was still able to increase hepatocyte fat deposition
(Figure 4A, bottom panels). When hepatocyte expression of genes
related to major lipid metabolic pathways were analyzed,
treatment with palmitoleate caused a significant increase in
hepatocyte mRNA levels of SREBP1c and FAS, and showed no
significant effect on hepatocyte mRNA levels of CPT1a and
VLDLr (Figure 4B) compared with controls. These results suggest
that increased lipogenesis appeared to account for an increase in
hepatocyte fat deposition brought about by palmitoleate treat-
ment. To address how palmitoleate increases hepatocyte FAS
expression, the FAS reporter assay was performed. Compared
with controls, treatment with palmitoleate increased SREBP1c
transcription activity at the basal condition (without insulin)
(Figure 4C). When insulin was supplemented, the effect of
palmitoleate on increasing SREBP1c transcription activity was
much more potent. Next, the chromatin immunoprecipitation
(ChIP) assay was performed. Compared with BSA or oleate,
palmitoleate treatment caused a marked increase in SREBP1c
binding to FAS promoter (Figure 4D). The latter appeared to
account for the effect of palmitoleate on increasing SREBP1c
transcription activity. Although promoting hepatocyte fat de-
position, palmitoleate increased hepatocyte Akt (Ser473) phos-
phorylation at both basal and insulin-stimulated conditions
(Figure 4E), indicating improvement of hepatocyte insulin
sensitivity.
Palmitoleate Decreases the Inflammatory Response in
Both Hepatocytes and Macrophages
The anti-inflammatory effect of palmitoleate was analyzed.
Compared with controls, palmitoleate-supplemented hepatocytes
exhibited a significant decrease in both basal and palmitate-
stimulated NF-kB p65 (Ser468) phosphorylation and TNFa and
IL-6 expression (Figure 5A and B). Additionally, treatment with
palmitoleate caused a significant decrease in NF-kB p65 (Ser468)
phosphorylation and TNFa and IL-6 expression in RAW
macrophages in a pattern similar to that in mouse primary
hepatocytes (Figure 5C and D). In combination with the above
results on hepatocyte fat deposition (Figure 4), palmitoleate
appears to dissociate hepatocyte inflammatory response from fat
deposition.
Discussion
The results from palmitoleate-supplemented mice support
a causal role for palmitoleate in the development of hepatic
Table 2. General metabolic characteristics.
BSA Oleate Palmitoleate
Body weight (g)
Prior to dosing 29.861.0 29.961.3 29.561.5
Post-dosing 30.461.5 29.961.3 29.461.5
Food intake (g/d/
mouse)
2.6860.0 2.7360.1 2.8660.1
Glucose (mg/dl) 216615 204611 170611
{*
Insulin (ng/ml) 1.660.3 1.560.2 1.060.3
Free fatty acids (mM) 0.460.1 0.460 0.560.1
Triglycerides (mg/dl) 37613 7 60.2 3761
HOMA-IR 10.861.7 10.261.2 5.761.7
{*
Male wild-type C57BL/6J mice, at 5–6 weeks of age, were fed an LFD for 12
weeks and supplemented with palmitoleate (600 mg/kg/d, conjugated with
bovine serum albumin (BSA) in phosphate-buffered saline (PBS)), oleate
(600 mg/kg/d), or BSA (in PBS) via oral gavages for the last 4 weeks. After the
feeding/supplementation regimen, mice were fasted for 4 hrs before collection
of blood samples. Data are means 6 SE, n=4–6.
{P,0.05 palmitoleate vs. BSA;
*P,0.05 palmitoleate vs. oleate. HOMA-IR is an index of insulin resistance
calculated according to the following equation. HOMA-IR = basal glucose
(mmol/l) 6basal insulin (mU/l)/22.5.
doi:10.1371/journal.pone.0039286.t002
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inducing fat deposition was observed in mouse primary hepato-
cytes. Significantly, palmitoleate is pro-lipogenic, evidenced by
increased hepatic expression of SREBP1c and FAS upon
palmitoleate treatment. Furthermore, palmitoleate treatment
activated SREBP1c transcription activity and increased the
binding of SREBP1c to FAS promoter in hepatocytes. These
aspects illustrate novel cellular mechanisms underlying how
palmitoleate brings about fat deposition in liver/hepatocytes
through stimulating lipogenesis. Initially, palmitoleate was thought
to suppress liver lipogenesis [14]. This conclusion, however,
appeared to be based only on a decrease in liver FAS expression in
mice upon palmitoleate infusion during clamp. A similar
conclusion was drawn in palmitoleate-supplemented KKAy mice
[15], but also is inappropriate because decreased liver FAS
expression occurred in a condition where palmitoleate-supple-
mented mice displayed a significant decrease in food intake. Given
that food restriction has a powerful effect on reducing hepatic
steatosis [23], the decrease in liver FAS expression in palmitoleate-
supplemented KKAy mice could be attributed solely to reduction
of food intake associated with palmitoleate dosing. In other words,
the conclusion drawn from KKAy mice needs to be validated in
mice upon pair-feeding. Because C57BL/6J mice were used in the
present study, the possibility that mice with different genetic
background respond differentially to palmitoleate can not be ruled
out. Nonetheless, neither of the two previous mouse studies
[14,15] provided data to demonstrate a direct effect of
palmitoleate on FAS expression in hepatocytes. In contrast, the
present study provided both in vivo and in vitro results to argue in
favor that palmitoleate stimulates hepatic events related to
lipogenesis. As such, the present study offers a reasonable
explanation for the positive correlation between the circulating
levels of palmitoleate and hepatic steatosis observed in human
subjects [16]. At this point, it is not sure why palmitoleate
supplementation increased the circulating levels of oleate (18:1n9)
Figure 2. Induction of hepatic steatosis while improving liver insulin sensitivity and decreasing liver inflammatory response in LFD-
fed mice. Male C57BL/6J mice, at 5–6 weeks of age, were fed a low-fat diet for 12 weeks and supplemented with palmitoleate (600 mg/kg/d), oleate
(600 mg/kg/d), or bovine serum albumin (BSA) via oral gavages for the last 4 weeks. (A) Liver fat deposition. Right panels, liver sections were stained
with H&E. Left panel, hepatic triglyceride levels. (B) Liver gene expression. SREBP1c, sterol-regulatory element-binding protein 1c; FAS, fatty acid
synthase; CPT1a, carnitine palmitoyltransferase 1a; VLDLr, very low density lipoprotein receptor; GK, glucokinase; and G6Pase, glucose-6-phosphatase.
(C) Liver insulin signaling. Livers of the treated mice were collected at 5 min after a bolus injection of insulin (1 U/kg) or PBS into the portal vein. Left
panels, Akt and phospho-Akt (Ser473) were examined using Western blot analyses; right panel, quantification of P-Akt/Akt. AU, arbitrary unit. (D) Liver
macrophages/Kupffer cells (left two panels, F4/80 staining; right panel, F4/80
+ cell fraction). (E) Liver NF-kB p65 and phospho-p65 (Ser468). (F) Liver
cytokine expression. For A – D and F, numeric data are means 6 SE, n=4–6.
{, P,0.05 and
{{, P,0.01 palmitoleate vs. BSA (in A and D) for the same
gene (in B and F) under the same condition (in C).
doi:10.1371/journal.pone.0039286.g002
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is pro-lipogenic.
Palmitoleate supplementation increased Akt (Ser473) phosphor-
ylation in both livers and mouse primary hepatocytes. These
effects further validate the insulin-sensitizing effect of palmitoleate
[14]. Significantly, stimulation of Akt phosphorylation by
palmitoleate was accompanied by increased fat deposition in
livers/hepatocytes. The development of hepatic steatosis is
thought to be largely due to insulin resistance [1,24]. Thus, the
present study indicates that palmitoleate dissociates hepatic
steatosis from insulin resistance. Likely, palmitoleate acts through
unrelated mechanisms to separately regulate lipogenesis and
insulin signaling in hepatocytes. As mentioned above, palmitoleate
directly increases hepatocyte SREBP1c activation, thereby bring-
ing about increased FAS expression. Meanwhile, palmitoleate
exhibits an anti-inflammatory property in hepatocytes (see below),
which appears to account for the insulin-sensitizing effect of
palmitoleate as the inflammatory status is a critical determinant of
insulin sensitivity in hepatocytes [25], as well as other metabolic
cells including adipocytes [26,27]. When these two palmitoleate-
driven events occur simultaneously, palmitoleate induces hepatic
steatosis while increasing insulin signaling. This view is consistent
with recent results from both human and mouse studies which
increasingly indicate that fat deposition is not necessarily
accompanied by insulin resistance [28,29]. Indeed, in certain
genetically modified mice, hepatic fat deposition is even inversely
related to insulin resistance [30,31], which is identical to the case
in the present study. For this reason, hepatic steatosis may be a cost
of improved insulin sensitivity at both systemic and hepatic levels.
Thus, cautions should be taken when considering palmitoleate for
insulin sensitization.
It is also a novel finding that palmitoleate supplementation
suppressed liver inflammatory response. Notably, palmitoleate
supplementation reduced the numbers of macrophages/Kupffer
cells, and decreased the phosphorylation of NF-kB and the
expression of proinflammatory cytokines in livers of the treated
mice. In a previous study with human hepatoma cells, palmitoleate
is shown to decrease palmitate-induced inflammatory signaling
Figure 3. Improvement of systemic insulin sensitivity. Male C57BL/6J mice, at 5–6 weeks of age, were fed a high-fat diet for 12 weeks and
supplemented with palmitoleate (PO) or bovine serum albumin (BSA) via oral gavages for the last 4 weeks. (A) Insulin tolerance tests (ITT). (B) Area
under curve (AUC) was calculated based on ITT. (C) Glucose tolerance tests (GTT). (D) AUC was calculated based on GTT. For A and C, mice were fasted
for 4 hrs and received an intraperitoneal injection of insulin (1 U/kg) (A) or glucose (2 g/kg) (C). (E) Hepatic levels of triglycerides. (F) Liver NF-kB p65
and phospho-p65 (Ser468). For A – E, data are means 6 SE, n=4–6.
{, P,0.05 and
{{, P,0.01 palmitoleate vs. BSA (in B, D, and E) for the same time
point (in A and C).
doi:10.1371/journal.pone.0039286.g003
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inflammatory effect of palmitoleate. This is also the case in the
present study. Upon palmitoleate supplementation, mouse prima-
ry hepatocytes exhibited a decrease in the phosphorylation of NF-
kB and the expression of proinflammatory cytokines. Because of
this, it is convincing that suppressing hepatocyte inflammatory
response contributes to the in vivo actions of palmitoleate on liver
inflammatory response. In the liver, macrophages/Kupffer cells
critically determine liver inflammatory status [32]. Considering
this, suppressing macrophage/Kupffer cell inflammatory response
likely also contributes to the in vivo anti-inflammatory actions of
palmitoleate. This view, indeed, is echoed by the fact that
treatment with palmitoleate decreased the phosphorylation of NF-
kB and the expression of proinflammatory cytokines in RAW
macrophages. However, it is not clear about proportional
contributions of hepatocytes and macrophages/Kupffer cells to
palmitoleate actions on suppressing liver inflammatory response.
It should be noted that decreased liver/hepatocyte inflamma-
tory response was accompanied by increased fat deposition in both
livers and primary hepatocytes in response to palmitoleate
supplementation. These effects were consistent with the results
from Huh7 cells, in which palmitoleate increased steatosis but
decreased the phosphorylation of JNK1/2 [19]. The underlying
mechanisms by which palmitoleate dissociates the inflammatory
response from steatosis remain to be elucidated, but could be
attributable to the effect of palmitoleate on promoting esterifica-
tion of free fatty acids [19]. Previously, a causal relationship
between fat deposition and the inflammatory response has been
established in hepatocytes [11,12]. When the results from Huh7
cells [19] and from mouse primary hepatocytes of the present
study were compared, the opposite consequences on the in-
flammatory response appear to be due to the differences in the
types of fatty acids, i.e., palmitate vs. palmitoleate, from which
triglycerides are synthesized. In other words, the type of fat
deposited, but not the content fat is the key determinant of
hepatocyte inflammatory response. The latter, as previously
demonstrated, inversely correlates insulin sensitivity in adipocytes
[26]. As additional evidence, a similar relationship between the
inflammatory response and insulin sensitivity was observed in
mouse primary hepatocytes. Collectively, it is obvious that the
inflammatory response, but not fat deposition, inversely correlates
with insulin sensitivity as discussed above.
In summary, the present study provides the first in vivo evidence
to support a unique role for palmitoleate in dissociating liver
inflammatory response from hepatic steatosis. Mechanistically, the
pro-lipogenic effect of palmitoleate is manifested by increased
Figure 4. Induction of hepatocyte fat deposition while improving insulin signaling. (A) Hepatocyte fat deposition. Mouse primary
hepatocytes were treated with palmitoleate (50 mM), oleate (200 mM), or BSA (in PBS) for 48 hrs in the presence or absence of palmitate (250 mM) for
the last 24 hrs and stained with Oil-Red-O or 1 hr. (B) Hepatocyte gene expression. Mouse primary hepatocytes were treated with palmitoleate
(50 mM) or BSA (in PBS) for 48 hrs. The expression of genes related to lipid metabolism was analyzed using real-time RT-PCR. ChREBP, carbohydrate
responsive element-binding protein; ACC1, acetyl-CoA carboxylase 1. (C) Hepatocyte SREBP1c transcription activity. Mouse primary hepatocytes were
transfected with a plasmid containing firefly luciferase reporter driven by SRE sequence on FAS gene (FAS-SRE-luc), or a control plasmid (pGL3-luc) for
24 hrs. After transfection, the cells were treated with palmitoleate (50 mM) or BSA for 48 hrs in the presence or absence of insulin (100 nM) for the last
24 hrs. (D) Hepatocyte ChIP assay. Mouse primary hepatocytes were treated with palmitoleate (50 mM), oleate (200 mM), or BSA for 48 hrs and
subjected to the ChIP assay using antibodies against SREBP1c. The resultant DNA was analyzed by PCR with primers amplifying SRE-1 on FAS
promoter. The input (control) contained 10% of each of the immunoprecipitants. (E) Hepatocyte insulin signaling. Cells were treated as described in
(B). Prior to harvest, the cells were treated with or without insulin (100 nM) for 30 min. Top two panels, the levels and phosphorylation state of Akt
(Ser473); bottom panel, quantification of P-Akt/Akt. AU, arbitrary unit. For B, C, and E, numeric data are means 6 SE. All experiments were performed
at least in quadruplicate.
{, P,0.05 and
{{, P,0.01 palmitoleate vs. BSA for the same gene (B) under the same condition (C and E).
doi:10.1371/journal.pone.0039286.g004
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Additionally, while promoting fat deposition, palmitoleate exhibits
a direct anti-inflammatory effect on both hepatocytes and
macrophages. Thus, palmitoleate supplementation could be useful
for suppressing hepatic inflammatory response and for insulin-
sensitization, but at a cost of inducing hepatic steatosis.
Materials and Methods
Animal Experiments
Wild-type C57BL/6J mice were maintained on a 12:12-h light-
dark cycle (lights on at 06:00). At 5–6 weeks of age, male mice
were fed an LFD (10% fat calories, detailed in Table 1) for 12
weeks and treated with palmitoleate (600 mg/d/kg body weight,
conjugated with BSA and suspended in phosphate-buffered saline
(PBS)), oleate (600 mg/d/kg body weight), or BSA via oral
gavages for the last 4 weeks. During the 12-week feeding/
treatment period, body weight and food intake of the mice were
recorded weekly. After the feeding/treatment regimen, mice were
fasted for 4 hrs before sacrifice for collection of blood and tissue
samples [33–35]. Liver samples were either fixed and embedded
for histological and immunohistochemical analyses or frozen in
liquid nitrogen and then stored at –80uC for further analyses
[25,34]. Some mice were fasted similarly and used for insulin and
glucose tolerance tests and insulin signaling analyses. For a separate
study, male wild-type C57BL/6J mice, at 5–6 weeks of age, were
fed an HFD (60% fat calories, detailed in Table 1) for 12 weeks
and treated with palmitoleate or BSA via oral gavages for the last 4
weeks in the same way used for LFD-fed mice. The treated mice
were then subjected to the assays to analyze hepatic steatosis and
liver inflammatory response as described for LFD-fed mice. All
animals received human care and all study protocols were
approved by the Institutional Animal Care and Use Committee
of Texas A&M University.
Insulin and Glucose Tolerance Tests
Mice were fasted for 4 hrs and received an intraperitoneal
injection of insulin (0.5 U/kg for LFD-fed mice and 1 U/kg for
HFD-fed mice) or D-glucose (2ug/kg). For insulin tolerance tests,
blood samples (5 ml) were collected from the tail vein before and at
15, 30, 45, and 60 min after the bolus insulin injection. Similarly,
for glucose tolerance tests, blood samples were collected from the
tail vein before and at 30, 60, 90 and 120 min after the glucose
bolus injection [26,36].
Measurement of Metabolic Parameters
The levels of plasma glucose, triglycerides, and free fatty acids,
as well as hepatic triglycerides were measured using metabolic
assay kits (Sigma, St. Louis, MO and BioVision, Mountain View,
CA). The levels of plasma insulin were measured using ELISA kits
(Crystal Chem Inc., Downers Grove, IL). Additionally, plasma
levels of glucose and insulin were used to calculate HOMA-IR, an
indicator of systemic insulin resistance, using the following
equation. HOMA-IR = basal glucose (mmol/l) 6 basal insulin
(mU/l)/22.5.
Lipid Profiling
Plasma and liver samples were subjected to lipid profiling. Total
lipids were extracted using chloroform/methanol (2:1, v/v) and
separated by thin-layer chromatography. Different lipid fractions
were analyzed by capillary gas chromatography [37].
Histological and Immunohistochemical Analyses
The paraffin-embedded liver blocks were cut into sections of
5 mm thickness and stained with H&E. In addition, the sections
were stained for the expression of F4/80 with rabbit anti-F4/80
(1:100) (AbD Serotec, Raleigh, NC) as previously described [26].
The fraction of F4/80-expressing cells for each sample was
calculated as the sum of the number of nuclei of F4/80-expressing
cells divided by the total number of nuclei in sections of a sample.
Figure 5. Suppression of inflammatory responses. Mouse primary hepatocytes and RAW macrophages were treated with palmitoleate (50 mM)
or BSA (in PBS) for 48 hrs. (A) Hepatocyte NF-kB p65 and phospho-p65 (Ser468). (B) Hepatocyte expression of proinflammatory cytokines. (C) RAW
macrophage NF-kB p65 and phospho-p65 (Ser468). (D) RAW macrophage expression of proinflammatory cytokines. For B and D, data are means 6
SE. All experiments were performed in quadruplicate.
{, P,0.05 and
{{, P,0.01 palmitoleate vs. BSA for the same gene.
doi:10.1371/journal.pone.0039286.g005
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Cell Culture and Treatment
Mouse primary hepatocytes were isolated from C57BL/6J
mice as previously described [34,37]. To address direct effects of
palmitoleate, the isolated hepatocytes were treated with
palmitoleate (50 mM), oleate (200 mM), or BSA (in PBS) for
48 hrs in the presence or absence of palmitate (250 mM) for the
last 24 hrs to induce fat deposition and the inflammatory
response. To examine lipid accumulation, the treated hepato-
cytes were stained with Oil-Red-O. To determine changes in
hepatocyte insulin signaling, the cells were treated with insulin
(100 nM) or PBS for 30 min prior to harvest. Cell lysates were
prepared and used to measure the levels of Akt1/2 and
phospho-Akt (Ser473) using Western blots. Additionally, lysates
of cells without insulin treatment were examined for the levels
of NF-kB p65 and phospho-p65 (Ser468). To analyze hepato-
cyte gene expression, the total RNA was prepared and subjected
to real-time RT-PCR. To gain insight into palmitoleate
stimulation of FAS expression, some hepatocytes were used to
examine the transcription activity of SREBP1c using the
reporter gene analysis and the ChIP assay detailed below.
Western Blots
Lysates were prepared from frozen tissue samples and
cultured cells. Western blots were conducted as previously
described [26,36]. The levels of NF-kB p65, phospho-p65
(Pp65, Ser468), Akt1/2, and phospho-Akt (P-Akt, Ser473) were
analyzed.
RNA Isolation, Reverse Transcription, and Real-time PCR
The total RNA was isolated from frozen tissue samples and
cultured hepatocytes. RNA isolation and real-time RT-PCR
were conducted as previously described [35]. The mRNA levels
were analyzed for SREBP1c, carbohydrate responsive element-
binding protein (ChREBP), ACC1, FAS, CPT1a, VLDLr,
glucokinase, glucose-6-phosphatase, TNFa, and/or IL-6.
Gene Transcription Reporter Assay
Mouse primary hepatocytes were transfected with a plasmid
containing firefly luciferase reporter driven by SRE sequence on
FAS gene (FAS-SRE-luc), or a control plasmid (pGL3-luc) for
24 hrs as previously described [37]. After transfection, the cells
were treated with palmitoleate (50 mM) or BSA for 48 hrs in the
presence or absence of insulin (100 nM) for the last 24 hrs. Cell
lysates were prepared and used to measure luciferase activity using
a kit from Progema (Madison, WI).
Chromatin Immunoprecipitation (ChIP) Assay
Mouse primary hepatocytes were treated with palmitoleate
(50 mM), oleate (200 mM), or BSA for 48 hrs. Nuclear extracts
were prepared and subjected to ChIP assay using the EZ-ChIP
TM
kit following the procedure provided (Millipore, Billerica, MA).
Briefly, nuclear extracts were immunoprecipitated with rabbit
anti-mouse SREBP1c antibody or donkey anti-rabbit IgG. The
resultant DNA was analyzed by PCR with primers amplifying
SRE-1 on FAS promoter as previously described [38].
Statistical Methods
Numeric data are presented as means 6 SE (standard error).
Two-tailed ANOVA or Student’s t tests were used for statistical
analyses. Differences were considered significant at the P,0.05.
Supporting Information
Figure S1 Liver lipid profile. Male C57BL/6J mice, at 5–6
weeks of age, were fed an LFD for 12 weeks and supplemented
with palmitoleate (PO), oleate (Ole), or bovine serum albumin
(BSA) via oral gavages for the last 4 weeks. (A) Liver fatty acid
profile in triglyceride fraction. (B) Liver fatty acid profile in fatty
acid fraction. Data are means 6 SE, n=4–6.
(TIF)
Figure S2 Staining of liver macrophages/Kupffer cells.
Male C57BL/6J mice, at 5–6 weeks of age, were fed an LFD for
12 weeks and supplemented with palmitoleate (PO), oleate (Ole),
or bovine serum albumin (BSA) via oral gavages for the last 4
weeks. Liver sections were stained for macrophages/Kupffer cells
(206). Arrows indicate F4/80
+ cells.
(TIF)
Figure S3 Quantification of hepatocyte fat deposition.
Mouse primary hepatocytes were treated with palmitoleate
(50 mM), oleate (200 mM), or BSA (in PBS) for 48 hrs in the
presence or absence of palmitate (250 mM) for the last 24 hrs and
stained with Oil-Red-O or 1 hr. Fat content was quantified using
the colorimetric assay. AU, arbitrary unit. Data are means 6 SE.
All experiments were performed at least in quadruplicates.
{,
P,0.05 palmitoleate vs. BSA or oleate under the same condition
(BSA or palmitate).
(TIF)
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